Latest Clinical Data News

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.

PYC Therapeutics reported a narrowed half-year loss of $22.8 million while progressing four RNA drug candidates through clinical stages. The company announced a major $653 million capital raising to extend its cash runway to 2030 and support ongoing development.

Adherium Limited has raised $6.7 million through a Placement and Institutional Entitlement Offer, positioning itself to expand its digital respiratory management solutions and advance value-based care contracts with US insurers.

Tetratherix Limited reveals promising interim results for TetraDerm, its scar prevention product, showing minimal scarring in patients after skin lesion surgeries. The product’s unique approach could reshape wound closure in a $US2.1 billion market.

Adherium Limited launches a A$7.52 million equity raising to fund commercial expansion of its Hailie SmartInhaler remote patient monitoring platform targeting asthma and COPD patients in the US. The company aims to scale patient numbers and progress towards value-based care contracts with major insurers.

Emyria has secured expanded funding from Medibank to support its Treatment-Resistant Depression and PTSD programs at a new clinic in Victoria, marking a significant step in its national mental health care rollout.

PYC Therapeutics has initiated a substantial capital raising effort, aiming to secure up to A$653 million to propel its four RNA therapeutic candidates through critical clinical milestones. The retail entitlement offer opens today, following a successful institutional placement.

BCAL Diagnostics has launched its Avantect blood tests for pancreatic and ovarian cancer with encouraging early uptake and is advancing its BREASTESTplus breast cancer test towards broader clinical use.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

Acadia Pharmaceuticals has received a negative vote from the European Medicines Agency’s committee on its application to market trofinetide for Rett syndrome in the EU, prompting plans for a re-examination request.

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.